Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia

Chemical Compounds

• Nilotinib 100%
• Developmental 69%
• Imatinib 56%
• Tyrosine Kinase Inhibitor 53%
• Bias Potential 27%
• Safety 16%

Medicine & Life Sciences

• Leukemia, Myelogenous, Chronic, BCR-ABL Positive 60%
• Dasatinib 39%
• 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 31%
• Imatinib Mesylate 16%
• Physicians 13%
• Protein-Tyrosine Kinases 12%
• Leukemia, Myeloid, Chronic Phase 9%
• Therapeutics 9%
• Decision Making 5%
• Comorbidity 5%
• Clinical Trials 4%
• Safety 4%
• Population 2%